Last reviewed · How we verify
NCT04876573
Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19
Phase 2 trial testing Cyproheptadine Hydrochloride 4 MG in Viral Pneumonia in 60 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Ciusss de L'Est de l'Île de Montréal |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 June 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 January 2022 |
Drugs / interventions tested
- Cyproheptadine Hydrochloride 4 MG — full drug profile →
Conditions studied
- Viral Pneumonia — all drugs for Viral Pneumonia →
- COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →
- Serotonin Syndrome — all drugs for Serotonin Syndrome →
- Platelet Dysfunction — all drugs for Platelet Dysfunction →
Sponsor
Ciusss de L'Est de l'Île de Montréal — full company profile →
Who can join
18 and older, any sex, with Viral Pneumonia or COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Pilot study for evaluating the feasibility, security and efficacy of the use of Cypropheptadine, an antihistaminic and antiserotonin drug, as an adjunct of the standardized treatment in a population of patient who are hospitalized and requiring oxygen therapy for COVID-19.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
Qu C, Fuhler GM, Pan Y. · · 2021 · cited 18× · PMID 34073529 · DOI 10.3390/ijms22115672
Verify or expand the search:
- PubMed search for NCT04876573
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cyproheptadine Hydrochloride 4 MG
Trials testing the same drug.
- NCT04820751 — Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial · Phase 3 · unknown
Other recruiting trials for Viral Pneumonia
Currently open trials in the same condition.
- NCT07238114 — Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors · active not recruiting
Other Ciusss de L'Est de l'Île de Montréal trials
Trials by the same sponsor.
- NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
- NCT06500143 — Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery · completed
- NCT06522698 — Optimizing Research Data Acquisition With Smart Pill Bottles · NA · not yet recruiting
- NCT06522711 — Virtual Reality for Anxiolysis and Pharmacological Sparing · NA · not yet recruiting
- NCT07112261 — Avatar Therapy in Virtual Reality for Treatment-Resistant Major Depressive Disorder: A Pilot Study · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04876573 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ciusss de L'Est de l'Île de Montréal
- Last refreshed: 6 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04876573.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing